The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) after an episode of acute pulmonary embolism (PE) is likely underestimated,…
Articles by Teresa Carvalho, MS
Low activity levels in a small RNA molecule called miR126 may be implicated in vascular remodeling — a hallmark feature…
Treatment with the approved therapy Uptravi (selexipag) safely reduces disease severity and improves heart and lung health in people…
A short treatment with Remodulin (injectable treprostinil) before initiating Orenitram (oral treprostinil) allows pulmonary arterial hypertension (PAH)…
Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases.
A ketogenic diet — one that’s low in carbohydrates and higher in fat  — given under medical supervision seems to…
Although pregnancy should be avoided by women with severe pulmonary hypertension (PH), close monitoring by a multidisciplinary team may…
Intravenous use of Uptravi (selexipag) is safe and well-tolerated by pulmonary arterial hypertension (PAH) patients temporarily unable to take this…
The Pulmonary Hypertension Association (PHA) has published a guide that aims to help people recently diagnosed with pulmonary…
VivaLNK’s wireless device can now be used to capture changes in heart rate and electrical activity in people with…
Remunity, an innovative pump for Remodulin (treprostinil) to treat adults with pulmonary arterial hypertension (PAH), has launched commercial…
Australia’s government has taken a step to ensure that Uptravi (selexipag), an oral therapy for pulmonary arterial hypertension (PAH), is…